Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate
Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women.[1][2] It was also used to suppress lactation in postpartum women.[3][4]
Combination of | |
---|---|
Estradiol benzoate | Estrogen |
Estradiol phenylpropionate | Estrogen |
Testosterone propionate | Androgen; Anabolic steroid |
Testosterone phenylpropionate | Androgen; Anabolic steroid |
Testosterone isocaproate | Androgen; Anabolic steroid |
Clinical data | |
Trade names | Estandron Prolongatum, Lynandron Prolongatum, Mixogen |
Other names | EB/EPP/TP/TPP/TiC |
Routes of administration | Intramuscular injection |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider |
The medication was provided in the form of 1 mL ampoules and 2 mL vials containing 1 mg/mL EB, 4 mg/mL EPP, 20 mg/mL TP, 40 mg/mL TPP, and 40 mg/mL TiC in an oil solution and was administered by intramuscular injection.[1][5][6] EB/EPP/TP/TPP/TiC reportedly has a duration of about 14 days.[7]
Estandron Prolongatum, Lynandron Prolongatum, and Mixogen were all introduced for medical use by 1956.[8][9] Oral tablet products with the same brand names of Estandron, Lynandron, and Mixogen, containing ethinylestradiol and methyltestosterone, were marketed around the same time, and should not be confused with the injectable products.[8][1][10] Estandron Prolongatum, Lynandron Prolongatum, and Mixogen remained marketed as late as the 1980s.[6][4][11] EB/EPP/TP/TPP/TiC appears to no longer be marketed.[12][13][14]
Route | Medication | Major brand names | Form | Dosage |
---|---|---|---|---|
Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
Normethandronea | Ginecoside | Tablet | 5 mg/day | |
Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
Prasterone (DHEA)b | – | Tablet | 10–100 mg/day | |
Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
AndroGel | Gel, cream | 1–10 mg/day | ||
Vaginal | Prasterone (DHEA) | Intrarosa | Insert | 6.5 mg/day |
Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template. |
References
- Hans Hermann Julius Hager; Walther Kern; Paul Heinz List; Hermann Josef Roth (29 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 141, 157, 185. ISBN 978-3-662-25655-8.
- Josef Kimmig (14 March 2013). Therapie der Haut- und Geschlechtskrankheiten. Springer-Verlag. pp. 508–. ISBN 978-3-642-94850-3.
- Helmuth Vorherr (2 December 2012). The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 201–. ISBN 978-0-323-15726-1.
- Defoort P, Thiery M, Baele G, Clement D, Dhont M (December 1987). "Bromocriptine in an injectable retard form for puerperal lactation suppression: comparison with Estandron prolongatum". Obstet Gynecol. 70 (6): 866–9. PMID 3684122.
- Current Medicine and Drugs. 1964. p. 32.
Mixogen Injection is now available in single vials of 2 ml which replace the 1 ml ampoules hitherto supplied. It is widely used for the suppression of lactation and the single 2 ml dose pack is specially designed for obstetric indications.
- Sharma CP, Chandy T (November 1989). "Influence of steroid hormones on protein-platelet interaction at the blood-polymer interface". Biomaterials. 10 (9): 609–16. doi:10.1016/0142-9612(89)90115-4. PMID 2611310.
Mixogen, one 1 ml ampoule contains oestradiol benzoate I.P., 1 mg, oestradiol phenyl propionate, 4 mg, testosterone propionate I.P., 20 mg, testosterone phenyl propionate B.P., 40 mg and testosterone isocaproate B.P., 40 mg.
- Ufer, Joachim (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5 ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.
- Kahr, H.; Müller, H. A. (1956). "Behandlung der Menstruationsstörungen". Konservative Therapie der Frauenkrankheiten. pp. 1–85. doi:10.1007/978-3-7091-5694-0_1. ISBN 978-3-7091-5696-4.
- "Neue Spezialitäten". Klinische Wochenschrift. 37 (13): 719–720. 1959. doi:10.1007/BF01478227. ISSN 0023-2173. S2CID 13380961.
- Front Matter. (1953). The British Medical Journal, 2(4835). Retrieved from http://www.jstor.org/stable/20312464
- Kaiser R (March 1984). "Duration of the climacteric syndrome in women treated by hormonal substitution and in controls". Maturitas. 5 (3): 207–13. doi:10.1016/0378-5122(84)90054-9. PMID 6727694.
- "Estradiol". Drugs.com.
- Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN 978-0-85369-840-1.
- "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.